HHS AL L-CARNITINE LEPIDIUM CAPSULES (Each capsule contains L-carnitine/ Lepidium meyenii/ L-Arginine/ Ferula elaeochytris 300mg/ 150mg/ 150mg/ 90mg)

Indications

• Arthritis
• Skin disorders
• Inflammatory diseases
• Oxidative stress-related conditions

Dosage

Children: Refer to established clinical guidelines or consult a healthcare professional for appropriate dosing.

Adults: Refer to established clinical guidelines or consult a healthcare professional for appropriate dosing.

Mechanism of action

The exact mechanism of action of elaeochytris is not well-defined in the literature. However, phytochemicals present in the plant may exert their effects through the modulation of inflammatory pathways, including the inhibition of pro-inflammatory cytokines and the activation of antioxidant enzymes. This suggests a role in reducing oxidative stress and inflammation.

Pharmacodynamics

Elaeochytris exhibits a range of pharmacodynamic effects, primarily attributed to its bioactive compounds. These compounds may influence immune response and cellular signaling pathways, contributing to its anti-inflammatory and antioxidant properties. The efficacy of elaeochytris in modulating these responses may vary depending on the concentration and form of the extract used.

Pharmacokinetics

The pharmacokinetics of elaeochytris is not extensively documented. However, like many herbal products, it is anticipated that absorption occurs through the gastrointestinal tract after oral administration. The distribution, metabolism, and excretion of its active compounds would likely depend on their chemical nature and solubility, with some compounds potentially undergoing hepatic metabolism. Further research is required to fully understand the pharmacokinetic profile.

Pregnancy

There is insufficient data on the safety of elaeochytris during pregnancy. Caution is advised when considering its use in pregnant women.

Breast-feeding

Limited information is available regarding the excretion of elaeochytris in human milk. Caution should be exercised when administering to breastfeeding mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Digestive disorders
• Respiratory issues
• Inflammatory conditions
• Pain relief
• Antimicrobial treatment

Dosage

Children: Refer to established guidelines; specific doses for children are not well-documented and should be determined based on professional advice.

Adults: Refer to established guidelines for specific preparations of Ferula; doses can vary based on the form used (e.g., extract, powder) and the condition being treated.

Mechanism of action

The active compounds in Ferula, particularly ferulic acid and other phenolic compounds, are thought to exert their effects through modulation of various biochemical pathways. These compounds may inhibit the production of pro-inflammatory cytokines and enzymes involved in the inflammatory process, thereby providing anti-inflammatory effects. Additionally, they may exhibit antioxidant activity, scavenging free radicals and protecting cells from oxidative stress.

Pharmacodynamics

Ferula extracts have been studied for their potential effects on gastrointestinal motility, respiratory function, and pain relief. The anti-inflammatory properties may be beneficial in conditions such as arthritis and other inflammatory disorders. Furthermore, the antimicrobial properties could offer therapeutic potential against certain bacterial infections.

Pharmacokinetics

The pharmacokinetics of Ferula species and their active components are not extensively characterized. However, it is known that phenolic compounds are generally well-absorbed in the gastrointestinal tract. The metabolism of these compounds typically involves conjugation processes in the liver, leading to various metabolites that may contribute to their biological effects. The elimination half-life and specific metabolic pathways can vary depending on the individual compounds and their formulations.

Pregnancy

There is insufficient reliable information regarding the safety of ferula during pregnancy. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Due to a lack of sufficient data, it is advised to exercise caution when using ferula while breastfeeding. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Cardiovascular diseases
• Erectile dysfunction
• Peripheral arterial disease
• Wound healing
• Muscle growth and recovery
• Immune system support

Dosage

Children: For paediatric dosing, it is important to refer to the BNF for Children for appropriate guidelines based on the child's age, weight, and clinical condition.

Adults: The typical dosage for adults varies based on the condition being treated, but common oral doses range from 2 to 30 grams per day, divided into multiple doses. For specific dosing recommendations, please refer to the BNF.

Mechanism of action

L-arginine is converted to nitric oxide by nitric oxide synthase (NOS), which is crucial for vascular function and blood flow regulation. NO activates guanylate cyclase, leading to increased levels of cyclic GMP, a secondary messenger that mediates vasodilation and other cellular responses. This pathway is vital in both the cardiovascular and immune systems, with different isoforms of NOS (eNOS, nNOS, iNOS) contributing to various physiological effects.

Pharmacodynamics

L-arginine has been shown to enhance immune responses, improve wound healing, stimulate growth hormone release, and support muscle hypertrophy and tissue repair. Its role in nitric oxide production aids in vasodilation, improving blood circulation and oxygen delivery to tissues, which is essential for recovery and regeneration.

Pharmacokinetics

L-arginine is absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours after oral administration. It is metabolized primarily in the liver and kidneys, with a half-life of approximately 1-2 hours. The bioavailability of L-arginine can be influenced by dietary intake and metabolic conditions.

Adverse effects

• Gastrointestinal disturbances
• Nausea
• Diarrhea
• Abdominal pain
• Hypotension
• Allergic reactions

Interactions

• Antihypertensive agents may have additive effects leading to increased hypotension
• Sildenafil and other medications for erectile dysfunction may have enhanced effects when used with L-arginine

Precautions

• Caution in patients with a history of asthma or allergies
• Use with caution in patients with hypotension
• Monitor blood pressure in patients taking antihypertensive medications

Pregnancy

The safety of L-arginine in pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

L-arginine is excreted in breast milk, and its safety during breastfeeding is not well established. Consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Powder for oral solution
• Capsules

Mechanism of action

Levocarnitine acts as a carrier molecule for long-chain fatty acids, transporting them into mitochondria for beta-oxidation, which is critical for energy production. It also exports acyl groups from subcellular organelles and cells to urine, preventing toxic accumulation. The mechanism of action includes interactions with carnitine transporters, translocases, and acetyltransferases. Additionally, it normalizes the brain's redox state and enhances urea synthesis in the liver, potentially activating the glucocorticoid receptor. L-carnitine's antagonistic effects on thyroid hormone action, including inhibiting its nuclear entry, contribute to its therapeutic applications.

Pharmacodynamics

Levocarnitine plays a significant role in lipid metabolism and energy production through its involvement in the transport of fatty acids into the mitochondria. A deficiency in carnitine can lead to various metabolic issues, including liver, heart, and muscle dysfunction. The therapeutic use of levocarnitine includes its ability to stimulate gastric and pancreatic secretions and treat hyperlipoproteinemias. The L-isomer of carnitine is specifically active in lipid metabolism, and its deficiency can be identified through biochemical markers such as low plasma concentrations of free carnitine and elevated acylcarnitine levels.

Pharmacokinetics

Levocarnitine is absorbed in the intestines and distributed throughout the body tissues. It is primarily metabolized in the liver, with excretion occurring via urine. The pharmacokinetics of levocarnitine can vary based on dietary intake, physiological status, and specific health conditions that may affect its metabolism and clearance. The bioavailability of levocarnitine may also be

Adverse effects

• Nausea
• Vomiting
• Abdominal cramps
• Diarrhea
• Fishy body odor
• Rash
• Seizures (rare)

Interactions

• Anticoagulants may have altered effects.
• Thyroid hormones may have altered action due to L-carnitine's peripheral antagonism.

Precautions

• Use with caution in patients with renal impairment.
• Monitor for potential interactions with other medications.

Pregnancy

Limited data is available on the use of levocarnitine during pregnancy. Use only if clearly needed and after assessing benefits versus risks.

Breast-feeding

Levocarnitine is excreted in human milk. Caution is advised when administered to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral solution
• Tablets
• Capsules

Indications

• Respiratory health support
• Digestive health improvement
• Antioxidant effects
• Anti-inflammatory effects

Dosage

Children: Refer to established herbal guidelines and consult with a healthcare provider for appropriate dosing, as specific doses for Lepidium in children are not standardized.

Adults: Refer to established herbal guidelines and consult with a healthcare provider for appropriate dosing, as specific doses for Lepidium are not standardized.

Mechanism of action

Lepidium exerts its effects through various bioactive compounds, including glucosinolates, which may be hydrolyzed to form biologically active metabolites. These metabolites are thought to influence cellular pathways associated with detoxification and antioxidant defense. Additionally, Lepidium may affect the regulation of inflammatory processes and promote gastrointestinal health through its fiber content and other phytochemicals.

Pharmacodynamics

The pharmacodynamics of Lepidium are not extensively characterized in clinical studies. However, its constituents, such as glucosinolates, have been shown to modulate enzyme activities involved in detoxification and antioxidant defense. These effects may contribute to its potential protective roles against oxidative stress and inflammation, although the exact mechanisms and pathways require further elucidation.

Pharmacokinetics

The pharmacokinetics of Lepidium, including absorption, distribution, metabolism, and excretion, are not well-defined due to the variability of its active compounds and the lack of standardized dosing forms. Some studies suggest that the bioavailability of its components may be influenced by the method of preparation and the presence of other dietary factors. More pharmacokinetic studies are needed to clarify these aspects.

Pregnancy

There is insufficient data on the use of lepidium during pregnancy. Avoid use unless the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether lepidium is excreted in human breast milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Enhancement of energy and stamina
• Support for sexual health and libido
• Nutritional supplement
• Support for mood and cognitive function

Dosage

Children: Refer to product-specific guidelines, as safety and efficacy in children have not been well established.

Adults: Refer to product-specific guidelines, as doses can vary widely based on formulation.

Mechanism of action

Meyenii is thought to exert its effects primarily through the modulation of endocrine and hormonal systems. Animal studies suggest that it may enhance the production of luteinizing hormone and follicle-stimulating hormone, which are involved in reproductive functions. Additionally, it may influence the levels of testosterone and estrogen, contributing to its adaptogenic properties.

Pharmacodynamics

Meyenii exhibits adaptogenic properties, helping the body to adapt to stress and promoting overall vitality. Its effects on energy levels and sexual health are attributed to its ability to modulate hormonal balance. The bioactive compounds in meyenii, including macaenes and macamides, may play a role in its effects on mood and cognition, although the exact pathways are not fully understood.

Pharmacokinetics

The pharmacokinetics of meyenii have not been extensively studied in humans. It is believed that its active compounds are absorbed in the gastrointestinal tract, but specific data on absorption, distribution, metabolism, and excretion are limited. Further research is needed to clarify these aspects and establish a comprehensive pharmacokinetic profile.

Adverse effects

• Gastrointestinal disturbances
• Headache
• Insomnia
• Nausea
• Diarrhea

Precautions

• Use with caution in patients with gastrointestinal disorders
• Monitor for potential hormonal effects

Pregnancy

Not enough reliable information available regarding safety during pregnancy, consult healthcare provider before use.

Breast-feeding

Insufficient data available, exercise caution and consult healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powdered root
• Capsules
• Liquid extract

Mechanism of action

Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.

Pharmacodynamics

Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.

Mechanism of action

Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases. L-Carnitine is a peripheral antagonist of thyroid hormone action in some tissues. It inhibits thyroid hormone entry into cell nuclei. In a controlled clinical trial, L-carnitine was shown to reverse or prevent some symptoms of hyperthyroidism. ... Mortality and metabolic consequences of acute ammonium intoxication in mice are reduced by pharmacologic admin of L-carnitine. The mechanism for this effect may have 2 components. L-Carnitine admin normalizes the redox state of the brain (perhaps by incr the avail of beta-hydroxybutyrate and/or acetyl-L-carnitine to the brain), and it incr the rate of urea synth in the liver, perhaps in part by activation of the glucocorticoid receptor. At least part of the protective effect is associated with flux through the carnitine acyltransferases, as analogs of L-carnitine that are competitive inhibitors of carnitine acyltransferases enhance the toxicity of acute ammonium admin. Thus, it has been proposed that L-carnitine incr urea synth in the liver by facilitating fatty acid entry into mitochondria, leading to incr flux through the beta-oxidation pathway, an incr of intramitochondrial reducing equivalents, and enhancement of ATP production. ... Levocarnitine is necessary for normal mammalian fat utilization and energy metabolism. It facilitates entry of long-chain fatty acids into cellular mitochondria, where they are used during oxidation and energy production. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Carnitine's primary mechanism of action is apparently attributable to its role as a cofactor in the transformation of free long-chain fatty acids into acylcarnitines for subsequent transport into the mitochondrial matrix. Carnitine is involved in the metabolism of ketones for energy and the conversion of branched-chain amino acids - valine, leucine, and isoleucine - into energy. /Carnitine/ L-Carnitine participates in a reversible transesterification reaction, in which an acyl group is transferred from coenzyme A to the hydroxyl group of L-carnitine ... /This reaction facilitates the/ transfer of long-chain fatty acids from cytoplasm ... /and/ chain-shortened /very-long-chain/ fatty acids from peroxisomes to mitochondria /and the/ modulation of the acyl-CoA/CoA ratio in cellular compartments.

Pharmacodynamics

Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The "vitamin BT" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Levocarnitine can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.